Clinical Trial Update: Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

View source ↗

Summary

A real-world comparison of chemo-immunotherapy regimens for metastatic non-small cell lung cancer with PD-L1 <50% is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Gazi University | Conditions: Nonsmall Cell Lung Cancer, Stage IV, Metastatic Nonsmall Cell Lung Cancer | Status: RECRUITING